Lin Reviews Data on Cilta-Cel in Multiple Myeloma


Yi Lin MD, PhD explains how results from CARTITUDE-1 impact the treatment landscape for relapsed or refractory multiple myeloma.

Yi Lin MD, PhD, a hematologist/oncologist, consultant, Division of Hematology, Department of Internal Medicine, enterprise leader, Cancer Regenerative Medicine, Biotherapeutics, and Biomanufacturing, Mayo Clinic Comprehensive Cancer Center, associate medical director, Center for Regenerative Biotherapeutics, and consultant, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, discusses the CARTITUDE-1 study (NCT03548207), which supports the use of ciltacabtagene autoleucel (cilta-cel; Carvykti) for the treatment of relapsed or refractory multiple myeloma.

Lin explains that the BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy, cilta-cel demonstrated deep and durable responses in CARTITUDE-1, which consisted of a heavily pretreated group of patients with relapsed/refractory multiple myeloma. The overall response rate, as published in The Lancet, was 97% (95% CI, 91.2%-99.4%), which included stringent complete response in 67% of patients. Moreover, the was a short time to first response of 1 month.


0:07 | Cilta-cel, also known as now Carvykti as a regulatory approved CAR T is an autologous CAR T that are made from patient's own white blood cells, a subgroup of white blood cells called T cells. B cells are genetically changed to be able to target cells that has BCAM or B-cell maturation antigen markers. And plasma cells, particularly myeloma cells can have a relatively higher expression of these markers on them. So, CARTITUDE-1 is the first registration study that led to the FDA approval where they're used in United States. In this particular trial, patients with multiple myeloma who has had at least 3 prior lines of treatment, and the main backbone of myeloma treatment, which includes a proteasome inhibitor, an image or immunomodulatory drug and a CD38 targeting monoclonal antibody.

1:21 | Based on those initial primary results, which [are] already published and peer reviewed, [the] FDA had approved its use now in United States. The approval is for patients who's had 4 prior lines of therapy, including exposure to those drugs that I had talked about.

Related Videos
Related Content